Acelyrin
Acelyrin's team is made up of biopharmaceutical executives with a proven track record in developing assets offering significant advantages over existing therapies.
In particular, they played a key role at Horizon Therapeutics in the development of a pipeline of assets recently acquired for $28 billion by Amgen, a renowned pharmaceutical company.
Acelyrin's current portfolio comprises three assets: izokibep (a biologic targeting IL-17), lonigutamab (an antibody targeting IGFI-R) and SLRN-517 (an antibody targeting cKIT).
Data on the efficacy and safety of Izokibep in indications such as psoriatic arthritis are particularly convincing.
As for lonigutamab, it could be used as a subcutaneous injection for thyroid eye disease (TED), offering easier administration and a more favorable dosing regimen than competing drugs.
